– Recommended Phase 2 dose for ziftomenib identified, pending FDA review –
– Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in NPM1-mutant and KMT2A-rearranged AML –
Read more at globenewswire.comKura Oncology Reports Second Quarter 2022 Financial Results
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.